Harvard Medical School, Lumera to develop new protein biochip
Lumera Corp. announced this week a collaborative agreement with Harvard Medical School (HMS) and the Harvard Institute of Proteomics, a division of HMS. Lumera and HMS will develop a next generation silicon chip substrate that combines Lumera's NanoCapture technology with HMS's NAPPA methodology (nucleic acid programmable protein arrays). The resultant 10,000-spot very high density protein arrays are expected to significantly increase the speed of drug discovery and life science research, according to a release.

"The 10,000-spot biochip is a very important step towards our ultimate goal of producing a whole proteome biochip," said Joshua LaBaer, Director of the Harvard Institute of Proteomics. "As we increase spot density, we are able to gather more data about proteins from a single experiment," LaBaer added.

The new Lumera protein arrays are critical to the bioscience and pharmaceutical markets that need faster methods for drug discovery, biomarker discovery and solving complex problems in systems biology. Using the new Lumera array, researchers will be able to analyze high-throughput expression of well over 10,000 discrete proteins, in biologically-active arrays built from available cDNA libraries.